Kaiser Peter 4

What Happened

• Peter Kaiser, Chief Development Officer of Ocular Therapeutix (OCUL), disposed of 2,967 shares on May 26, 2026, for a reported weighted-average price of $8.20 per share, totaling approximately $24,329. This was a sale (S) executed under an automatic instruction and was not a discretionary trade.

Key Details

• Transaction date: 2026-05-26 (reported on Form 4 filed 2026-05-28) — filing appears timely.
• Price: weighted average $8.20; individual sale prices ranged from $8.1549 to $8.2550.
• Reason/footnote: Sold pursuant to a durable automatic sale instruction (adopted April 9, 2024) as a sell-to-cover to satisfy tax withholding for restricted stock units that vested May 22, 2026 (Footnote F1).
• Multiple trades: shares sold in multiple transactions across the stated price range; filer offers to provide per-price details on request (Footnote F2).
• Shares owned after transaction: not specified in the provided filing.

Context

• This was a routine sell-to-cover tied to RSU vesting and an automatic instruction — common for meeting tax obligations and not necessarily an indicator of the insider’s view on the company’s stock. The filing discloses the weighted-average price and the non-discretionary nature of the sales.